XGX Pharma ApS: Financial statements 2021
CVR: 32289290
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
XGX Pharma ApS (CVR 32289290) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 14,515,287 and a net result of DKK 7,248,505 compared with DKK 6,004,347 the year before. That is a decrease of 4.7% compared with the year before. Equity in the 2021 report amounted to DKK 13,168,867. The solvency ratio was 61.9%. The company had 3 employees in the financial year.
- Gross Profit
- DKK 14,515,287
- Profit/Loss
- DKK 7,248,505
- Equity
- DKK 13,168,867
- Total Assets
- DKK 21,257,411
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 14.5 mio. | 7.2 mio. | 13.2 mio. | 3 |
| 2020 | - | 15.2 mio. | 6 mio. | 12.9 mio. | 3 |
| 2019 | - | 11.7 mio. | 8.4 mio. | 11.4 mio. | 3 |
| 2018 | - | 1.6 mio. | 27 t. | 59 t. | 1 |
| 2017 | - | 104 t. | -189 t. | 32 t. | - |
Official annual report
Find more companies like XGX Pharma ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
XGX Pharma ApS has published its annual report for 2020. Gross profit came to DKK 15,225,623, and the net result was DKK 6,004,347.
About XGX Pharma ApS
XGX Pharma ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named VITAL PHARMA NORDIC ApS and VITAL PHARMA NORDIC HOLDING ApS. The management consists of Jens-Nikolaj Schøier. The board consists of Per Anders Larnholt (chair) and Johan Frödin. The company is owned by Unimedic Pharma AB. The company has 6 employees (2026). In 2025, the company reported a gross profit of DKK 32,338,381 and a net result of DKK 16,074,119 compared with DKK 4,453,433 the year before. Equity in the 2025 report amounted to DKK 30,787,180.